Qiming Weekly | Top 10 News from Qiming Venture Partners Portfolio Companies Vol.24, 2026.8.4

Editor's Note: In 2026, the Qiming Weekly has been upgraded and refreshed, with regular weekly updates featuring only ten major developments from Qiming Venture Partners' portfolio companies, covering funding progress and breakthroughs.

In the wave of technology and innovation, every step entrepreneurs take deserves to be recorded. Qiming Venture Partners will continue to accelerate and empower entrepreneurs, and join you in following the milestone moments of our portfolio companies.

Major Partnerships

01/ UBTECH Partners with Thai Universities to Build Embodied AI Development Ecosystem

Recently, the 2026 Thailand-China Cooperation Expo opened at the IMPACT Exhibition Center in Bangkok. Qiming Venture Partners portfolio company UBTECH (09880.HK), together with Thai listed IT firm SVOA, made a major exhibition appearance, showcasing for the first time in Southeast Asia its product matrix including the industrial humanoid robot Walker S2 and the wheeled industrial humanoid robot Cruzr Y1. On the first day of the expo, Thai Prime Minister Anutin Charnvirakul visited the UBTECH booth during his tour, receiving a detailed briefing on how industrial humanoid robots improve production efficiency and reduce labor costs.

During the expo, UBTECH signed a strategic cooperation memorandum with the Field and Industrial Robotics Research Center at King Mongkut's University of Technology Thonburi (KMUTT-FIBO). The two parties will jointly build an embodied AI humanoid robot secondary development ecosystem for ASEAN, supporting the intelligent upgrading of Thailand's manufacturing industry.

02/ Unisound Reaches Strategic Cooperation with Hello Inc.

Recently, Qiming Venture Partners portfolio company Unisound (09678.HK) reached a strategic cooperation with Hello Inc., a leading domestic inclusive mobility and local life services platform. The two parties will jointly explore more possibilities for AI-enabled mobility services, focusing on core scenarios such as Robotaxi intelligent cockpits and customer service system upgrades.

According to the cooperation plan, the two parties will jointly promote the deep integration of Unisound's U2 large model with Hello Inc.'s Robotaxi cockpit system, endowing Robotaxi with natural language dialogue, passenger intent recognition, emotional interaction, and proactive service capabilities. They will also jointly develop multiple types of active response functions, including large luggage identification assistance and emergency audio-visual warnings, further enhancing the intelligence, safety, and service availability of Robotaxi. Through the combination of large models, multi-modal perception, and edge intelligence capabilities, Robotaxi is expected to evolve from an "unmanned vehicle" to a "mobile intelligent agent" with proactive service capabilities.

03/ Hesai Technology's Thousand-Line LiDAR ETX Wins New Design Win from Great Wall Motor

Recently, Qiming Venture Partners portfolio company and global leader in 3D perception technology Hesai Technology (NASDAQ: HSAI; 02525.HK) announced that its automotive-grade ultra-long-range thousand-line LiDAR ETX has successfully secured a new design win from Great Wall Motor, with mass production expected to begin by the end of 2026 and deliveries to follow.

Addressing the ever-increasing safety demands of intelligent driving, high-performance LiDAR is becoming a critical enabler for improving perception accuracy and safety in complex scenarios. Hesai ETX is the world's highest line-count, longest-range automotive-grade high-performance LiDAR platform, supporting multiple thousand-line configurations including 1080-line, 2160-line, and 4320-line setups. Hesai ETX features world-leading range and small-object recognition capabilities, achieving detection up to 600 meters at maximum and 400 meters at 10% reflectivity, with clear identification of small objects such as water-filled barriers (120x60cm) at 300 meters, small animals (60x40cm) at 280 meters, and small wooden blocks (15x25cm) at 150 meters. ETX is equipped with Hesai Technology's globally pioneering photon isolation and waveform decoding engine innovations, significantly reducing false positive and false negative rates and further enhancing the safety and reliability of intelligent driving.

04/ Tigermed Completes Strategic Acquisition of Shanghai Baicheng

Recently, Qiming Venture Partners portfolio company and leading integrated biopharmaceutical and medical device R&D service platform Tigermed (300347.SZ, 03347.HK) formally completed the full strategic acquisition of Baicheng Medical. This acquisition represents an important move by Tigermed to align with global biopharmaceutical R&D trends, optimize internal resource allocation, and strengthen its full-industry-chain layout, providing more efficient, one-stop pharmaceutical supply chain services for global innovative drug development.

Rui Wang, Vice President of Tigermed and Head of Pharmaceutical Supply Chain Services, stated: "As the globalization trend in innovative drug development continues to deepen, the importance of clinical trial supply chains is becoming increasingly prominent. After joining Tigermed, Baicheng Medical will leverage the Group's global layout and integrated service system to further upgrade its supply chain service capabilities. Going forward, we will continue to strengthen our global resource integration capabilities and professional operational capabilities, providing clients with more efficient, flexible, and reliable solutions, accelerating the advancement of global innovative drug and medical device R&D, and bringing more innovative treatment options to patients."

Product Launches

Insilico Medicine Releases Industry's First "Drug Discovery Benchmark Assessment"

To address data contamination issues in public evaluation standards and more accurately measure AI capabilities in real-world drug discovery tasks, Qiming Venture Partners portfolio company and generative AI-driven clinical-stage biotechnology company Insilico Medicine (03696.HK) recently released the "Drug Discovery Benchmark Assessment" (DDD Benchmarks), simultaneously launching a BaaS business centered on benchmark assessment, open to all institutions dedicated to developing cutting-edge AI for drug discovery or researching the application of benchmark models in this field.

Dr. Alex Zhavoronkov, Founder and CEO of Insilico Medicine, stated: "The rapid evolution of AI has made one question urgently pressing: can these models actually make new drugs? For over a decade, our team has been building and validating generative AI across the entire drug discovery workflow, nominating 31 preclinical candidate compounds within six years and advancing a fully AI-driven discovered and designed drug to Phase III clinical trials. The DDD Benchmarks testing system externalizes this experience into rigorous, standardized benchmarks available for industry-wide use. On the path toward pharmaceutical superintelligence, only by examining genuine hard capabilities rather than answer-memorizing abilities can we ensure that AI truly delivers high-quality, differentiated new drugs and genuinely extends healthy lifespan on a global scale."

R&D Progress

01/ YaoYing Medical Co-organizes 6th Annual Meeting of Shanghai Medical Association's Psychosomatic Medicine Branch

Recently, the 6th Annual Academic Meeting of the Psychosomatic Medicine Branch of the Shanghai Medical Association was successfully held. Qiming Venture Partners portfolio company Shanghai YaoYing Hospital participated deeply as a co-organizer, joining over a hundred experts and scholars from across the country to explore standardized diagnosis and treatment and cutting-edge directions in mind-body integration.

As a representative of the co-organizing institution, Dr. Haoying Shi, President of Shanghai YaoYing Hospital, stated in her opening address that psychosomatic medicine is the bridge connecting physical and mental health, and an important practical vehicle for the "biological-psychological-social" modern medical model. YaoYing Medical has gradually built a cross-professional team-based psychological protection network, with particular focus on children and adolescents. Since establishing the "YaoXinYu" Adolescent and Family Mental Health Center in 2023, through the coordinated efforts of psychiatrists, psychotherapists, and family education instructors with surrounding schools and communities, psychological services have been extended from the clinic to campuses and families.

Looking ahead, Dr. Shi proposed two directions for industry collaboration: first, building a tiered collaborative psychosomatic service network, promoting standardized diagnosis and treatment from tertiary hospitals down to the community level, and exploring the use of intelligent assistive tools to empower grassroots general practitioners, lowering the threshold for identifying psychosomatic issues and strengthening the foundation of tiered diagnosis and treatment; second, leveraging YaoYing's mature international medical cooperation network to continue building academic exchange bridges between China and abroad, introducing international cutting-edge intervention concepts while exporting local clinical practices, particularly in the field of adolescent mental health, to develop replicable service paradigms that allow psychosomatic medicine to deliver greater social value.

02/

Shize Biotech Completes Full Enrollment for Phase II Registration Clinical Trial of Universal Cell Therapy for Parkinson's Disease

Recently, Qiming Venture Partners portfolio company Shize Biotech announced that its self-developed allogeneic universal "off-the-shelf" iPSC-derived dopaminergic neural progenitor cell injection XS411 for the treatment of idiopathic Parkinson's disease has successfully completed full enrollment in its nationwide multi-center Phase II registration clinical trial.

The trial adopts the internationally widely recognized PROBE blinded assessment design (Prospective, Randomized, Open-label, Blinded Endpoint), which, compared with traditional single-arm open-label clinical studies, provides significantly higher-grade evidence-based medicine. While accommodating the clinical implementation characteristics of cell therapy, it further improves study quality through randomized controlled design and blinded endpoint assessment, providing more reliable efficacy evidence for subsequent Phase III registration clinical trials and marketing approval.

03/

Pulnovo Medical's PADN System Secures Market Approval in Malaysia and Baltic States

Qiming Venture Partners portfolio company and global pioneer in breakthrough therapies for pulmonary hypertension and heart failure Pulnovo Medical recently announced a series of major advances in multinational regulatory access. Following market approval in Indonesia for its self-developed Pulmonary Artery Denervation (PADN) system — including the PADN circular pulmonary artery radiofrequency ablation catheter and the PHD360 pulmonary artery radiofrequency ablation instrument — the company has consecutively obtained regulatory access in Malaysia and the three Baltic states (Estonia, Latvia, and Lithuania) for the treatment of Group 1 Pulmonary Hypertension.

Cynthia Chen, Chairwoman and President of Pulnovo Medical, stated: "This series of密集 approvals spanning Asia and Europe represents a highly symbolic step in Pulnovo Medical's global commercialization layout, and further confirms our long-term commitment to regional markets. Taking Malaysia as an example, as early as 2024, we took the lead in launching the PADN-Columbus trial for Group 2 Pulmonary Hypertension here and successfully completed the enrollment of the first batch of patients. This made Malaysia the earliest ASEAN country to participate in the clinical exploration of Pulnovo's original technology. From the cross-national clinical research collaboration back then to the formal approval to enter Malaysia today and now covering the entire Baltic region, this is the fruition of our years of deep cultivation of regional clinical cooperation and insistence on opening multilateral markets with hardcore clinical value."

04/

AHBIO Invited to Inaugural CPIC Great Power New Drugs Global Conference

Recently, the inaugural CPIC Great Power New Drugs Global Conference (China Pharmaceutical Innovation Conference) was grandly held at the Shanghai National Exhibition and Convention Center. Qiming Venture Partners portfolio company AHBIO Co-founder and Chief Scientific Officer Dr. Chengyong Yang was invited to attend and delivered a speech at a conference panel session, sharing AHBIO's drug R&D philosophy, as well as research progress in the functional cure of chronic hepatitis B, the ASO innovative technology platform, and the latest clinical progress of the company's core pipeline AHB-137.

Dr. Yang focused on sharing the latest clinical research results of AHB-137. Notably, in treatment-naïve chronic hepatitis B patients, after 16 weeks of AHB-137 monotherapy and 24 weeks off treatment, the functional cure rate reached 70% in a specific population (baseline HBsAg 100-1000 IU/mL), fully validating the tremendous potential of the ASO technology route in achieving functional cure of hepatitis B. This research result not only brings new treatment hope to hepatitis B patients but also provides new ideas for exploring treatment strategies for chronic hepatitis B.

05/

CANbridge Pharmaceuticals Announces GORININ® Expansion to North African Market

Recently, Qiming Venture Partners portfolio company CANbridge Pharmaceuticals (01228.HK) announced that it has fully launched the registration application process and commercialization preparation for GORININ® (velaglucerase alfa for injection) in key North African markets, with all pre-launch preparations being comprehensively advanced.

GORININ was approved for marketing on May 13, 2025. It is the first domestically developed and produced long-term enzyme replacement therapy in China suitable for adolescents and adults aged 12 and above with Type I and Type III Gaucher disease, representing a biologic innovative drug that can replace comparable imported products. The innovative technology employed by GORININ is enzyme modification and directed evolution; combined with continuous flow manufacturing technology in the future, it can be extended to other similar drugs beyond Gaucher disease, achieving scaled and batched production. Going forward, GORININ's platformized technology will significantly reduce development costs, allowing patients to access safe and effective domestic enzyme replacement drugs that they can afford. The company is currently conducting a registration clinical trial approved by the National Medical Products Administration (NMPA) to expand GORININ's applicable population to children aged 2 to under 12.

PAST REVIEWS

Qiming Perspectives | Duane Kuang of Qiming Venture Partners: Embrace the Cycle, Navigate the Cycle, AI Will Be an Ultra-Long Technology Cycle Qiming Weekly | Top 10 News from Qiming Venture Partners Portfolio Companies Vol.21, 2026.6.23 Qiming Headlines | Qiming Venture Partners and Portfolio Companies Win Multiple Awards Including TOP4 Best VC Institution in China at ChinaVenture 2025 Rankings

Founded in 2006, Qiming Venture Partners currently manages 11 USD funds and 7 RMB funds, with total assets under management reaching $9.5 billion. Since its inception, the firm has focused on investing in early and growth-stage outstanding enterprises in Technology and Healthcare innovation.

To date, Qiming Venture Partners has invested in over 580 high-growth innovative companies, of which more than 210 have listed on the New York Stock Exchange, NASDAQ, Hong Kong Exchanges and Clearing, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through mergers and acquisitions. Over 80 companies have become recognized unicorns or super-unicorns in their respective industries.

Many companies in Qiming Venture Partners' portfolio have grown into the most influential players in their fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ:BILI, 09626.HK), Zhihu (NYSE:ZH, 02390.HK), Roborock (688169.SH), Hesai Technology (NASDAQ:HSAI, 02525.HK), UBTECH (09880.HK), WeRide (NASDAQ:WRD, 0800.HK), HyperStrong (688411.SH), Insta360 (688775.SH), Unisound (09678.HK), Biren Technology (06082.HK), Zhipu (02513.HK), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ:ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ:SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), SinoCellTech (688520.SH), Insilico Medicine (03696.HK), AHBIO, Yuanxin Technology, MediLink Therapeutics, LaNova Medicines, StepFun, and others.